Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Neuroendocrine × Radiopharmaceuticals × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 1 Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1 Advanced Head and Neck Carcinoma 1

Interventions

Cisplatin 11 Everolimus 10 Nivolumab 7 Etoposide 7 Temozolomide 5 Ipilimumab 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 atezolizumab 4 Irinotecan 4 Capecitabine 4 pembrolizumab 3 avelumab 3 Paclitaxel 3 Fluorouracil 3 surufatinib 2 sintilimab 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Positron Emission Tomography Computed Tomography 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 EC regimen 2 Disulfides 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡